Compare Global X Defense Tech ETF (SHLD) vs Travere Therapeutics Inc. Common Stock (TVTX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Global X Defense Tech ETF vs Travere Therapeutics Inc. Common Stock — how do they compare? Global X Defense Tech ETF trades at $59.99 (market cap $6.34B), while Travere Therapeutics Inc. Common Stock trades at $53.44 (market cap $5.02B). The key difference: Global X Defense Tech ETF is the larger of the two by market cap, and Travere Therapeutics Inc. Common Stock is trading nearer its 52-week high, Global X Defense Tech ETF nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Global X Defense Tech ETF for 45 Days and Travere Therapeutics Inc. Common Stock for 0 Days on average.
| SHLD | TVTX | |
|---|---|---|
Market Cap | $6.34B | $5.02B |
Volume | 1,295,513 | 2,060,842 |
Sector | Sector/Thematic | Health |
52-Week High | $78.02 | $67.52 |
52-Week Low | $58.20 | $26.79 |
Typical Hold Time | 45 Days | 0 Days |
Enterprise Value | — | $5.15B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
SHLD (Global X Defense Tech ETF) trades at $59.34, down 0.82% on the day amid bearish technical signals. The ETF faces selling pressure with 13 bearish moving average signals versus zero bullish. Recent institutional buying activity from Focus Financial Network and Balefire LLC indicates professional interest in defense technology exposure. The fund focuses on emerging defense technologies and cybersecurity with global diversification beyond traditional U.S. defense names.
Defense sector tailwinds from increased global military spending provide growth catalysts, though valuation metrics remain unavailable. Geopolitical tensions and European rearmament initiatives support the investment thesis, but sector concentration and political budget risks require monitoring. The ETF's technology focus differentiates it from traditional defense funds but carries execution risks in emerging defense technologies.
Travere Therapeutics (TVTX) trades at $51.80, down 0.42% on the day, with a neutral technical signal. The company reported strong revenue growth but persistent net losses, with a 2025 net income margin of -7.35%. Recent news includes new data presentations for its key drug FILSPARI and a CEO transition. Analyst consensus is strongly bullish with an 83.33% buy rating and a $70.60 price target, suggesting significant upside from the current price.
The outlook for TVTX hinges on the commercial success of FILSPARI, which shows promising sales growth, but profitability remains a challenge. Key risks include execution of the CEO transition, competitive pressures in nephrology treatments, and the company's ability to achieve sustained profitability. The high valuation multiples relative to negative earnings present a risk-reward balance for investors.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Global X Defense Tech ETF
SHLD tracks the Global X Defense Tech Index, targeting companies that lead the technological transformation of the defense sector. It focuses on pure-play innovators in cybersecurity, artificial intelligence, robotics, and advanced military systems, excluding traditional commercial aerospace to maintain a high level of thematic purity.
Read more on SHLD →About Travere Therapeutics Inc. Common Stock
Travere Therapeutics Inc. is a biopharmaceutical company focused on rare kidney and metabolic diseases. Its lead product, FILSPARI (sparsentan), is an oral medication for adults with IgA nephropathy, and it also markets Thiola for cystinuria.
Read more on TVTX →
